Posts by Sandra Ansanay-Alex
SFNV Forum: Precision Nutrition
Swiss Food and Nutrition Impact Forums are one-hour online seminars featuring Swiss and international experts. The 21 October 2024 event is about Precision Nutrition. Precision Nutrition is an emerging area of research that focuses on the relationship between genes and other individual-specific information, nutrition and health. We know that we need to move…
Read MorePlair brings its Rapid-C+ on the market
Rapid-C+, an advanced real-time air microbial detector that sets new standards in environmental monitoring, is now on the market. The device was designed by Plair, a Geneva-based startup. Rapid-C+ uses patented biofluorescent particle counting technology to detect and identify viable contaminants in real time. Its state-of-the-art features include laser-based light scattering and fluorescence…
Read MoreThe Swiss Institute of Bioinformatics has launches the Centre for Pathogen Bioinformatics
The Centre aims to enhance Switzerland’s role in global pathogen bioinformatics research, providing expertise and services to federal authorities and the international research community. This will support pandemic preparedness and real-time pathogen surveillance. The Centre will contribute to the pathogen response and public health strategies at both national and international scale. It will…
Read More“Bringing meaning back to the healthcare professionals”
Appointed Dean of the Faculty of Medicine at the University of Geneva, Professor Antoine Geissbuhler, is also Director of Teaching and Research at the HUG, and BioAlps President. In an interview to Pulsation Magazine, he has set himself the ambitious goal of meeting the many challenges facing medical education today. What would you…
Read MoreMultiwave Technologies partners with Aix Marseille University
Multiwave Technologies brings to market a portable MRI device powered by metamaterial technologies and AI software. The partnership includes joint research and the financing of 5 portable MRI units to be deployed in medical and sport labs across Aix-Marseille University sites for research purposes. Developing a new generation of MRI equipment… This is the aim of…
Read MoreMonitor your blood pressure with OptiBP, a Biospectal application
Patients can measure their blood pressure in 30 seconds by placing their fingertip on the camera lens of a smartphone. “Finally, measuring blood pressure anywhere and anytime has become so easy that dramatically more people will be able to manage their cardiovascular disease better from now on,” comments Jens Krauss, Head of the…
Read MoreBioLizard chooses Biopôle for its Swiss subsidiary
BioLizard is a Belgian bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry. Liesbeth Ceelen, PhD, CEO of BioLizard, said: “We aim to meet the need for expertise and tools for digital transformation of biotech companies, including for AI-enabled, user-friendly software and data infrastructure.…
Read MoreOryl Photonics raises CHF 830,000 in seed funding
The Vaud-based startup announces the successful conclusion of a CHF 830,000 seed fundraising. The round is backed by Swiss investors, including CADFEM International AG, S2S Ventures and several business angels. This is a significant achievement for Oryl Photonics, a company pioneering the development of highly efficient solubility measurement for pharmaceutical and life science…
Read MoreCSEM Inventor Award granted to spaceCoder
Shedding Light on Precision: CSEM spaceCoder technology is a game changer in the field of precision measurement In the realm of scientific innovation, where light illuminates, shadows also cast opportunities for advancement. Researchers at CSEM (Centre Suisse d’Electronique et de Microtechnique) have ingeniously harnessed this principle with their groundbreaking “spaceCoder” technology, heralding a…
Read MoreSuccessful € 5 Million Capital Increase for GeNeuro
GeNeuro, a Geneva-based biopharmaceutical company focusing on treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and severe neuropsychiatric consequences of COVID-19 (post-COVID), has successfully completed a €5 million capital increase. The increase involved a private placement of 4,666,901 new GeNeuro ordinary bearer shares for specialized and strategic…
Read More